Novo Nordisk’s Comeback Narrative Gains Steam from Analyst Upgrade, Clinical Data and Canadian Access Push

The Danish drugmaker has clawed its way back from a deep March trough, and a flurry of developments — from a bullish analyst initiation to fresh clinical proof and a novel home-delivery service — is giving investors fresh reasons to take another look. After plumbing a low of €30.48, the stock has rebounded more than 31% to close at €40.17 on Wednesday, racking up a 20% gain over the past 30 days. Yet the year-to-date picture remains negative at minus 10%, leaving room for debate about whether the recovery has legs.

Hedgeye, a research firm, kicked off coverage on May 13 with an audacious call: it sees an upside of 52% to 117% for Novo Nordisk shares. The driver, according to the analysts, is the accelerating take-up of oral obesity treatments in the U.S. market. Hedgeye projects that monthly prescriptions for oral semaglutide could reach 3.6 million by the end of 2026 — a figure underpinned by its earnings-per-share estimate of $5.06, well above the consensus of $3.55. The current price-to-earnings multiple of roughly 13.6 sits at a clear discount to the industry average of 16.8, which the firm argues represents a structural mispricing.

Technically, the stock is showing signs of life. It now trades about 18% above its 50-day moving average. Analysts point to a stable daily close above $47 as a buy signal, with the next target zone around $54. The near-term direction, however, will hinge on weekly U.S. prescription data for the oral pill — the first real-time gauge of whether demand is tracking toward Hedgeye’s ambitious forecast.

While the stock fightback draws attention, Novo Nordisk is also advancing on the operational front. On May 13, the company launched Novo Nordisk Care Rx in Canada, a home-delivery service in partnership with Rexall Pharmacy. The program offers patients telephone consultations with a pharmacist and discreet home delivery of key GLP-1 drugs — Ozempic, Wegovy and Rybelsus. Iain Graham, head of Novo Nordisk Canada, said the move reflects the desire of many Canadians for a simpler way to manage chronic diseases. The initiative may not be flashy, but it addresses a critical bottleneck in the GLP-1 business: ensuring patients stick with long-term therapy through easy access and support.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The strategic push comes on the back of solid first-quarter numbers. Novo Nordisk reported revenue of 96.8 billion Danish kroner (around $15.2 billion) for the first quarter of 2026, above market forecasts. The U.S. launch of the oral Wegovy variant in January added momentum in the obesity segment. On an adjusted basis, however, revenue dipped 4% at constant exchange rates, due to a one-off effect from a U.S. rebate program. Nonetheless, management raised its 2026 guidance, betting that the demand wave for GLP-1 products will sustain its pace.

Fresh clinical ammunition arrived at the European Congress on Obesity in Istanbul. Results from the Phase 3 OASIS 4 and STEP UP trials showed that 27% of patients receiving the high 7.2 mg dose of Wegovy lost at least 15% of their body weight within 24 weeks. More strikingly, early responders to the oral semaglutide pill achieved an average weight reduction of 21.6% over 64 weeks. With more than two million patients already using the oral version, the ability to identify those who respond quickly could sharpen treatment protocols and expand the addressable population.

In parallel, Novo Nordisk completed the last step of its retreat from cell therapy. On May 12, the company transferred the Parkinson’s disease program STEM-PD — which held FDA Fast Track designation — to Cellular Intelligence, an AI-driven biotech firm. No financial terms were disclosed beyond Novo Nordisk receiving equity and potential milestone payments. The sale formally closes a portfolio pruning that began in late 2025 and underscores the group’s singular focus on metabolic disorders.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

The combination of a cheap valuation, expanding access initiatives, encouraging clinical data and a leaner pipeline has created a narrative that many analysts believe is still under-appreciated. The market’s next cue will come from the weekly prescription counts for oral semaglutide in the U.S. — a stream of data that could prompt consensus upgrades and propel the stock toward the levels Hedgeye and others are targeting. Whether the bounce turns into a sustained uptrend will depend on whether those numbers match the ambition.

Ad

Novo Nordisk Stock: New Analysis - 14 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69329521 |